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onset of sustained ischemia, and was maintained for the duration of 20 min of coronary
occlusion. The IN group received 15 min of waiting period followed by 20 min of ischemia.
The ischemic and the non-ischemic tissues in the IN and IH hearts were separated and
processed for tissue adenosine triphosphate (ATP), creatine phosphate (CP), lactate and
glycogen determination.
Results: Ischemia decreased ATP, CP and glycogen content (by 67%, 73% and 73%
respectively) and caused 13-fold accumulation of lactate in the ischemic vs. the non-
ischemic area in the IN hearts. However, mild, regional hypothermia preserved ATP and
glycogen stores in the ischemic area of IH rabbits by 43% and 83% respectively (i.e.
1.20±0.11 µmol/g in the IH vs. 0.84±0.06 µmol/g in the IN group, p<0.05 for ATP; and
1.32±0.15 mg/g in the IH vs. 0.72±0.07 mg/g in the IN group, p<0.05 for glycogen). In
addition, mild regional hypothermia caused a trend towards the preservation of CP by
14% in the ischemic tissue (0.81±0.15 µmol/g in the IH group vs. 0.71±0.07 µmol/g in the
IN group).
Conclusion: It is likely that the mechanism whereby mild regional hypothermia reduces
infarct size is by slowing the metabolism of the crucial high energy phosphate, ATP. This
is the first study to show that in a model of regional ischemia local therapy with very mild
reductions in myocardial temperature preserves ATP within the ischemic risk zone.
1041-100 Hydrochlorothiazide Further Improves Survival During 
Angiotensin-Converting Enzyme Inhibitor Therapy After 
Experimental Myocardial Infarction
Bart Westendorp, Regien G. Schoemaker, Hendrik Buikema, Wiek H. van Gilst, Dirk J. 
van Veldhuisen, University of Groningen, Groningen, The Netherlands, University 
hospital of Groningen, Groningen, The Netherlands
Background: Efficacy of ACE inhibitor (ACEi) treatment after myocardial infarction may
be positively influenced by concomitant sodium depletion with diuretics, as is reported in
treatment of renal proteinuric disease and hypertension.
Hypothesis: Treatment with the diuretic hydrochlorothiazide (HCT) augments beneficial
effects of chronic ACEi treatment after MI.
Methods: Rats were subjected to coronary ligation to induce MI. After 2 weeks, rats were
randomized to 15 mg/kg/day quinapril only (QUI, n=44), or 50 mg/kg/day HCT in addition
to quinapril (QUI-HCT, n=46). Survival was checked for 62 weeks. LV function and neuro-
hormones were measured in survivors after 62 weeks and in a separate batch of rats
treated for 35 weeks according to the same procedures (QUI, n=6; QUI-HCT, n=5).
Results: Results are shown in the table. Until week 35 survival was significantly
improved by additional HCT (p<0.05). Urinary protein excretion and left ventricular end-
diastolic pressures (LVEDP) were decreased in QUI-HCT rats at week 35. Plasma renin
activity (PRA) was lower in QUI-HCT rats at 35 weeks. After 62 weeks, differences had
waned off.
Conclusion: Adding of HCT to QUI treatment further improved survival, neurohumoral
status, and proteinuria during the early chronic phase of experimental post-MI LV dys-
function. The results suggest that combined therapy with diuretics and ACEi can be a
safe treatment to improve prognosis of post-MI LV dysfunction.
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1042-77 Haptoglobin Polymorphism Is Associated With Short-
Term Mortality and Heart Failure in Patients With 
Diabetes and Acute Myocardial Infarction
Mahmoud Suleiman, Doron Aronson, Michael Kapeliovich, Walter Markiewicz, Haim 
Hammerman, Shimon A. Reisner, Rachel Lotan, Michael Shochat, Nina S. Levy, Andrew 
P. Levy, Rambam, Haifa, Israel
Introduction: Patients (pts) with diabetes presenting with acute myocardial infarction
(AMI) have a poor in-hospital outcome primarily due to an increased incidence of death
and heart failure. The susceptibility to diabetic complications is partially determined by
genetic factors. Haptoglobin (Hp) phenotype is related to the risk of developing both
microvascular and macrovascular complications of diabetes. We prospectively tested the
hypothesis that Hp phenotype is related to the outcome of pts with diabetes presenting
with AMI.
Methods: We enrolled 798 consecutive pts with AMI. The primary endpoint was 30-days
mortality or heart failure. Infarct size was determined by echocardiography on day 2-3.
Multivariate logistic regression was used to calculate adjusted ORs and to test for inter-
action between Hp phenotype and diabetes with respect to the primary endpoint.
Results: At 30-days, 237 patients (29.7%) died or developed heart failure. Multivariate
logistic regression identified a strong protective effect of Hp 1-1 phenotype with regard to
the primary endpoint of 30-days mortality or heart failure (OR for Hp 1-1 versus Hp 2-1 or
Hp 2-2: 0.43; 95% CI 0.22-0.84, P = 0.01). The interaction between Hp phenotype and
diabetes was highly significant in unadjusted (P = 0.008) and adjusted (P = 0.005) logis-
tic regression models. In a stratified analyses, Hp 1-1 phenotype was not related to out-
come among pts without diabetes (Adjusted OR 0.78; 95% CI 0.33-1.82, P = 0.56). By
contrast, Hp 1-1 phenotype was associated with a strong protective effect with regard to
the primary endpoint among pts with diabetes (Adjusted OR 0.21; 95% CI 0.07-0.62, P =
0.005). Among pts with diabetes, Hp 1-1 was also associated with a smaller infarct size
compared with Hp 2-1/2-2 (echocardiographic wall motion score index 1.70 ± 0.03 vs
1.45 ± 0.07, P = 0.005), whereas in pts without diabetes there was no significant differ-
ence. Conclusion: Hp phenotype may be an important genetic marker that affects the
outcome of patients with diabetes and AMI. Better understanding of the mechanism
underlying Hp effect may help to reduce morbidity and mortality in patients with diabetes
in the setting of AMI.
1042-78 Does Chronic Infection With Chlamydia Pneumoniae 
Influence the Prognosis of Acute Coronary Syndromes? 
Insights From a Nested Matched Case-Control 
Substudy of the GUSTO IV Acute Coronary Syndromes 
Trial
Cynthia M. Westerhout, Judy Gnarpe, Wei-Ching Chang, Elliot S. Barnathan, Eric 
Boersma, Stefan James, Robert M. Califf, Maarten L. Simoons, Paul W. Armstrong, 
University of Alberta, Edmonton, Canada
Background: Prior studies of chronic Chlamydia pneumoniae(Cpn) infection and
adverse outcomes of ACS are inconclusive, small in sample size and used non-standard-
ized antibody detection methods. Thus, in well-defined non-ST-elevation(NSTE) ACS pts
followed for 1yr, serologically defined chronic Cpn infection may be a significant predictor
of adverse outcomes. Methods: This case-control substudy of GUSTO-IV ACS (n=7800)
randomly selected 295 pts who had 30-day(30d) death or myocardial infarction
(MI)(cases) (with 90% power). Cases were matched to 295 controls on age, sex, CK-MB
and smoking status(potential confounder of Cpn infection). Cpn IgG and IgA titers were
measured in baseline serum with microimmunofluorescence technique. Conditional
logistic regression identified predictors of 30d death/MI and 1yr death. Results: Controls
were similar to cases in Cpn IgG >=1:32 (85% v 80% p>0.1) and IgA >=1:16 (43% v 49%
p=0.07). After baseline adjustment, troponin T was a significant predictor of 30d death/
MI, but CRP, IgG and IgA were not. Given the value of long-term prognosis, a subset was
drawn from 590-pt cohort:138 pts who died at 1y plus its partner in the existing matched
pair who survived 1y(n=276). Pts with IgG>=1:256 were at twice the risk of 1y death and
was independent of CRP, also a significant predictor of 1y death(Figure). Conclusions:
Whereas chronic Cpn infection was not associated with 30d death/MI, it emerged as a
significant independent predictor of long-term death even in the presence of CRP. 
1042-79 Impact of Altered Expression Balance of Matrix 
Metalloproteinases and Tissue Inhibitor of 
Metalloproteinases Genes on Coronary Plaque Rupture: 
Results From Quantitative Tissue Analysis Using Real-
Time Reverse Transcriptase-Polymerase Chain 
Reaction Method
Shuichiro Higo, Shinsuke Nanto, Takeo Higashikata, Hatsue Ishibashi-Ueda, Aiji 
Sakamoto, Hitonobu Tomoike, Masakazu Yamagishi, Kansai Rosai Hospital, Amagasaki, 
Japan, National Cardiovascular Center, Suita, Japan
Background:Previous immunohistochemical studies demonstrated overexpression of
matrix metalloproteinases (MMPs) at the ruptured coronary sites in acute coronary syn-
drome. However, few data exist regarding quantitative analysis of gene expression of
MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), in human cor-
onary plaque. Therefore, gene expression of MMPs and TIMPs was quantitatively deter-
mined by real-time RT-PCR.
Method and Results:Tissue samples of the coronary plaque were obtained from 28 cor-
onary patients underwent directional atherectomy. Amounts of the cDNAs for MMP-1, 2,
3 and 9, and TIMP-1, 2, 3 in each cDNA mixture were determined by real-time RT-PCR
method, and normalized with glutaraldehyde 3-dehydrogenase as a reference gene. In
tissue samples from 8 patients with unstable disease. the gene for MMP-9 (5.00 + 1.57)
was significantly augmented to express than those from 20 patients with stable patients
(1.97 + 1.14, p<0.05). There were no statistical significance in MMP-1 (0.41 + 0.19 Ver-
sus 0.34 + 0.10), MMP-2 (2.04 + 0.34 Versus1.85 + 0.22) and MMP-3 (1.36 + 1.06 Ver-
sus 0.28 + 0.08) gene expression. Although the expression levels of TIMP-1, TIMP-2 and
TIMP-3 genes tended higher in unstable (30.19 +5 .11, 4.45 + 0.89 and 6.85 + 2.14) than
that in stable patients (26.33 + 6.24, 3.75 + 1.06 and 4.68 + 1.69), the ratios of MMP-9/
Table
Mortality 
(%)
Urinary protein 
(mg/24h)
LVEDP (mm 
Hg)
PRA (ng Ang1/
mL/h)
QUI week 35 11 9.5±0.9 10±2 192±27
QUI-HCT week 35 0* 7.4±0.5* 7±2 100±19*
QUI week 62 23 9.5±0.6 12±3 73±9
QUI-HCT week 62 22 8.0±0.6 12±3 65±6
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TIMP-1 and MMP-9/TIMP-3 were still higher in the lesions from unstable (0.24 + 0.07
and 1.47 + 0.39) than in those from stable (0.09 + 0.05 and 0.53 + 0.19) patients. Immu-
nohistochemistry localized both MMP-9 and TIMPs in macrophages some of which were
expressed in the fibrous cap of the ruptured plaque.
Conclusions: Upregulation of MMP-9 in the plaques from unstable coronary patients
was disproportional to that of TIMPs, suggesting that active degradation of extracellular
matrix persists in advanced coronary lesions particularly in those from clinically unstable
patients.
1042-80 Ischemia Modified Albumin Improves the Sensitivity and 
Negative Predictive Value of Standard Cardiac 
Biomarkers for the Diagnosis of Myocardial Ischemia
Saif Anwaruddin, James L. Januzzi, Jr., Kent B. Lewandrowski, Elizabeth Lewandrowski, 
Massachusetts General Hospital, Boston, MA
Introduction: We examined the utility of ischemia modified albumin (IMA), both alone
and with standard biomarkers of cardiac myonecrosis, for the assessment of patients
with suspected myocardial ischemia in the emergency department.
Methods: 200 consecutive patients presenting to the emergency department with symp-
toms suggestive of myocardial ischemia were evaluated.Measurement of troponin I (TnI),
creatine kinase-MB (CK-MB), and myoglobin (Myo) were performed on each patient
using a quantitative bedside point of care assay (Biosite, LaJolla, CA) as well as mea-
surement of the IMA with the Albumin Cobalt Binding (ACB) assay (Ischemia Technolo-
gies, Denver, CO). Every case (including history, physical, electrocardiogram, stress test
and angiography, if applicable) was reviewed, in a blinded fashion, by a cardiologist. A
clinical diagnosis of ischemia was assigned based on these data, and then correlated to
the results of the biomarker testing.
Results: 13% of the patients were judged to have myocardial ischemia by clinical data.
Compared to those patients without ischemia, patients with a clinical diagnosis of
ischemia were older (70.5 ± 16.9 vs 65.4 ± 16.9 years, p<0.001), and were more likely to
have had a prior diagnosis of coronary artery disease (67% vs 26%, p<0.001) or prior
revascularization (28% vs 10%, p=0.002). Furthermore, those patients with ischemia
were more likely to have congestive heart failure (20% vs 6%, p=0.002). Utilizing a cut-
point of 90 unit/ml, we found the ACB assay to have 83% sensitivity and 30% specificity
for the diagnosis of ischemia, with a negative predictive value of 92%. Among the same
group of patients, the triple screen of CK-MB/TnI/Myo had a sensitivity of only 57%. The
combination of IMA/CK-MB/TnI/Myo increased the sensitivity for the detection of
ischemia to 97%, with a negative predictive value of 92%.
Conclusion: When used in patients with suspected myocardial ischemia, the ACB assay
for IMA has high sensitivity and negative predictive values. Furthermore, IMA measure-
ment improves the sensitivity of CK-MB/TnI/Myo for the detection of acute coronary
ischemia.
1042-81 Increased Expression of Myeloid Related Protein in 
Infiltrated Neutrophils in Coronary Atherosclerotic 
Plaques of Patients With Unstable Angina
Shoichi Miyamoto, Masaki Ikemoto, Makiko Ueda, Takahiko Naruko, Akira Itoh, Koji 
Hasegawa, Masatoshi Fujita, Kyoto University, Kyoto, Japan, Osaka City University, 
Osaka, Japan
Background: Myeloid related protein (MRP) is expressed in infiltrated neutrophils and
macrophages during inflammatory reactions. The purpose of this study was to investi-
gate; (1) whether serum MRP levels are increased in patients with unstable angina (UA),
(2) whether MRP levels are upregulated in coronary atherosclerotic plaques of patients
with UA. Methods: Serum MRP levels were measured using a sandwich enzyme-linked
immunosorbent assay system which was newly developed in our laboratory in 53
patients [64±13 (SD) years] with UA (Braunwald’s classification II and III) and 39 patients
(64±11 years) with stable angina (SA), and serum C reactive protein (CRP) levels were
also measured. In addition, we immunohistochemically studied the presence of MRP in
directional coronary atherectomy specimens, obtained from the different 25 patients
(59±10 years) with UA and 26 patients (56±12 years) with SA. The presence of MRP
immunoreactivity was quantified using a computer-aided planimetry. For the identification
of the cell types which stain positive for MRP, immunodouble staining was also per-
formed. Results: There were no significant differences between the two groups regard-
ing age, sex, risk factors, and angiographic findings. Serum MRP levels were significantly
higher in patients with UA than in SA (3.25±3.08µg/ml vs. 0.77±0.31µg/ml, p<0.0001).
Serum CRP levels were also significantly higher in patients with UA than in SA
(3.11±6.14mg/dl vs. 0.19±0.20mg/dl, p<0.005). The percentage of MRP positive area
was significantly higher in patients with UA than in those with SA (18.3±14.2% vs.
1.3±2.4%, p<0.0001). In patients with UA, the immunodouble staining clearly revealed
that MRP was expressed in infiltrated neutrophils and occasional macrophages. Conclu-
sion: The measurement of serum MRP levels and the immunohistochemical approach
are useful for the differentiation between UA and SA. MRP may be involved in vulnerabil-
ity of coronary atherosclerotic plaques in patients with UA.
1042-82 White Blood Cell Count Predicts Higher Risk of 
Intermediate-Term Outcomes in Patients Stabilized 
After Acute Coronary Syndromes: Observations From 
the SYMPHONY and 2nd SYMPHONY Trials
Gustavo B.F. Oliveira, L. Kristin Newby, Lauren Lindblad, Leopoldo S. Piegas, Freek W. 
Verheught, Robert A. Harrington, Judith S. Hochman, Harvey D. White, Frans Van de 
Werf, Christopher B. Granger, Duke Clinical Research Institute, Duke University Medical 
Center, Durham, NC, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
Background: As a marker of inflammation, the white blood cell count (WBCc) is widely
available, has WHO-defined laboratory assay standards and excellent interassay preci-
sion (coefficient of variation <3%), and has been shown to be associated with acute cor-
onary syndromes (ACS) at presentation and clinical outcomes. Little is known about later
WBCc in initially stabilized ACS patients. Methods: Our hypothesis was that WBCc
would be an independent predictor of death (at 90 days and 1 year), and recurrent
ischemic events at 90 days, in patients with unstable angina or myocardial infarction who
were clinically stable for at least 12 hours. WBCc were collected at 3 days (median) in
9015 patients from the SYMPHONY and 2nd SYMPHONY trials. The continuous and
dichotomized (median 7600/mm3) relationships of WBCc with baseline characteristics
and outcomes were examined. Results: Patients with higher WBCc were younger and
heavier, more often male, diabetic and current smokers, had higher estimated creatinine
clearance, more congestive heart failure, but less often had prior ACS. Statins, beta-
blockers, aspirin and percutaneous coronary intervention were used more frequently in
these patients. In adjusted models, the HRs per 10-increase in continuous WBCc were
2.4 (1.35-4.28) and 1.89 (1.14-3.12) for 90-day and 1-year death, respectively (P-
value<0.0001). Conclusion: WBCc is a strong predictor of death and recurrent ischemic
events in the full spectrum of ACS patients, even after an initial stabilization.
1042-83 Detection of Increased Blood Temperature in the 
Coronary Sinus of Patients With Coronary Artery 
Disease: The Impact of Temperature Measurements on 
Prognosis
Sophia Vaina, Konstantinos Toutouzas, John Mitropoulos, Eleftherios Tsiamis, Christos 
Pitsavos, Harissios Boudoulas, Christodoulos Stefanadis, Hippokration Hospital, Athens, 
Greece
Background: Widespread inflammation is observed in patients (pts) with coronary artery
disease (CAD), possibly resulting in increased temperature in the coronary sinus (CS)
blood. Our study aimed to test whether increased CS blood temperature in pts with CAD
is related to prognosis. Methods: We enrolled 47 pts undergoing coronary angiography,
for evaluation of recent onset of chest pain. Temperature measurements were performed
by a CS thermography catheter (Medispes, ZWG, Switzerland), previously validated. As
temperature difference (∆T) was designated the difference between CS and right atrium
(RA) blood temperature. Study's end-points were: recurrent angina, myocardial infarction
(MI) and cardiac death. Mean follow-up period was 8.7±3 months. Results: The mean
blood temperature was lower in the RA compared to the CS (38.07±0.3
vs.38.28±0.4°C,p<0.001). During follow-up 2 pts suffered from MI, 1 died after coronary
artery bypass surgery and 6 had a repeat revascularization procedure. The incidence of
adverse cardiac events in pts with ∆T>0.25°C was 34.78% and in pts with ∆T<0.25°C
was 4.16%(p<0.01). The relative risk of adverse cardiac events in pts with ∆T>0.25°C
was significantly increased (RR = 8.36,p<0.05). A Cox survival plot stratified for the cut-
off point showed a clear relationship between ∆T and event-free survival (Figure). Con-
clusions: This study suggests, that increased blood temperature in the CS is a predictor
for adverse cardiac events in a mid-term follow-up period in pts with CAD.
Outcomes by Baseline WBC Count
WBC> 
7600/mm3
WBC< 
7600/mm3
Hazard Ratio (95% CI) P-value
90-day Death, % 1.9 1.1 3.0 (1.70-5.34) 0.0002
90-day Death or MI, % 7.1 5.9 1.5 (1.13-2.10) 0.007
90-day Death /MI /SRI, % 9.3 8.1 1.4 (1.05-1.82) 0.02
1-year Death, % 2.8 1.1 2.0 (1.23-3.31) 0.005
